US 12,419,894 B2
Ribociclib tablet
Rui Costa, Basel (CH); Arnaud Grandeury, Helfrantzkirch (FR); and Bindhumadhavan Gururajan, Basel (CH)
Assigned to Novartis AG, Basel (CH)
Filed by Novartis AG, Basel (CH)
Filed on Dec. 11, 2024, as Appl. No. 18/977,228.
Application 18/977,228 is a continuation of application No. 18/588,259, filed on Feb. 27, 2024.
Application 18/588,259 is a continuation of application No. 17/805,956, filed on Jun. 8, 2022, granted, now 12,064,434, issued on Aug. 20, 2024.
Application 17/805,956 is a continuation of application No. 17/003,771, filed on Aug. 26, 2020, abandoned.
Application 17/003,771 is a continuation of application No. 15/564,534, granted, now 10,799,506, issued on Oct. 13, 2020, previously published as PCT/IB2016/052136, filed on Apr. 14, 2016.
Claims priority of provisional application 62/148,240, filed on Apr. 16, 2015.
Prior Publication US 2025/0127785 A1, Apr. 24, 2025
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 31/519 (2006.01); A61K 9/20 (2006.01); A61K 9/28 (2006.01); A61K 31/496 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/2027 (2013.01); A61K 9/2054 (2013.01); A61K 9/2077 (2013.01); A61K 9/284 (2013.01); A61K 31/496 (2013.01)] 4 Claims
OG exemplary drawing
 
1. A coated tablet comprising a tablet core and an immediate release coating, wherein the tablet core comprises a disintegrant and 254.4 mg ribociclib succinate, and wherein the tablet has a dissolution profile produced according to United States Pharmacopeia (USP) <711> by dissolving the tablet using a rotating basket at 100 rpm at 37° C. in 900 mL of dissolution media of pH 1 HCl, pH 2 HCl, pH 4.5 acetate buffer, or pH 6.8 phosphate buffer, wherein the dissolution profile corresponds to FIG. 4, wherein LEE011 is ribociclib.